Sugi Predict

Sugi Predict / Compounds / SCHEMBL2136484

SCHEMBL2136484

SCHEMBL2136484

Cc1cccn2cc(C(=O)Nc3nc4cc(-c5cc(Cl)ccc5Cl)ccc4[nH]3)nc12

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.42
▸ RAB9A P51151 6/20 0.42
▸ POLB P06746 2/20 0.42
▸ KLF5 Q13887 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ PKM P14618 1/20 0.41
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ ABL1 P00519 4/20 0.39
▸ RPS6KA3 P51812 2/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HRH4 Q9H3N8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2135031 0.90 NPC1 (0.47) NPC1RAB9APOLBKLF5TDP1
SCHEMBL2134001 0.89 NPC1 (0.45) NPC1RAB9APOLBKLF5TDP1
SCHEMBL2135220 0.87 NPC1 (0.39) NPC1RAB9APOLBKLF5TDP1
SCHEMBL2135751 0.86 ABL1 (0.43) NPC1RAB9APOLBKLF5KDM4E
SCHEMBL2135556 0.84 NPC1 (0.40) NPC1RAB9APOLBKLF5TDP1
SCHEMBL2135790 0.83 PDE2A (0.37) NPC1RAB9APOLBKDM4EALDH1A1
SCHEMBL2136735 0.83 DDR2 (0.38) KDM4EALDH1A1ABL1
SCHEMBL2133207 0.82 NPC1 (0.38) NPC1RAB9APOLBKLF5KDM4E
SCHEMBL2138344 0.82 MTOR (0.41) NPC1RAB9APOLBKLF5KDM4E
SCHEMBL2136538 0.82 NPC1 (0.36) NPC1RAB9APOLBKLF5TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 — — US claimed
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 — — US disclosed
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 — — US disclosed
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 — — US disclosed
WO-2010126745-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP NPC1 289/4885RAB9A 2165/4885POLB 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.